High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it’s important for retail traders to take note.
\This activity came to our attention today through Benzinga’s tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BNTX often signals that someone has privileged information.
Today, Benzinga’s options scanner spotted 20 options trades for BioNTech. This is not a typical pattern.
The sentiment among these major traders is split, with 55% bullish and 20% bearish. Among all the options we identified, there was one put, amounting to $28,000, and 19 calls, totaling $795,467.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $80.0 and $120.0 for BioNTech, spanning the last three months.
Analyzing Volume & Open Interest
In today’s trading context, the average open interest for options of BioNTech stands at 491.43, with a total volume reaching 1,256.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in BioNTech, situated within the strike price corridor from $80.0 to $120.0, throughout the last 30 days.
BioNTech Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BNTX | CALL | TRADE | BEARISH | 01/16/26 | $7.2 | $4.6 | $5.5 | $105.00 | $82.5K | 1.1K | 107 |
| BNTX | CALL | SWEEP | NEUTRAL | 01/15/27 | $37.7 | $36.4 | $36.4 | $80.00 | $69.1K | 82 | 19 |
| BNTX | CALL | TRADE | BULLISH | 01/16/26 | $11.0 | $9.4 | $11.0 | $100.00 | $44.0K | 1.2K | 31 |
| BNTX | CALL | TRADE | NEUTRAL | 01/21/28 | $42.2 | $39.9 | $41.04 | $87.50 | $41.0K | 0 | 34 |
| BNTX | CALL | TRADE | NEUTRAL | 01/21/28 | $42.3 | $39.6 | $40.98 | $87.50 | $40.9K | 0 | 24 |
About BioNTech
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company’s oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Following our analysis of the options activities associated with BioNTech, we pivot to a closer look at the company’s own performance.
BioNTech’s Current Market Status
- With a volume of 556,316, the price of BNTX is up 2.91% at $109.16.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 53 days.
What The Experts Say On BioNTech
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $142.0.
- An analyst from Goldman Sachs upgraded its action to Buy with a price target of $142.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics.